Search hospitals > Michigan > Detroit
Children's Hospital of Michigan
Claim this profileDetroit, Michigan 48201
Global Leader in Human Immunodeficiency Virus Infection
Global Leader in Leukemia
Conducts research for Brain Tumor
Conducts research for Sickle Cell Anemia
Conducts research for Tumors
309 reported clinical trials
18 medical researchers
Summary
Children's Hospital of Michigan is a medical facility located in Detroit, Michigan. This center is recognized for care of Human Immunodeficiency Virus Infection, Leukemia, Brain Tumor, Sickle Cell Anemia, Tumors and other specialties. Children's Hospital of Michigan is involved with conducting 309 clinical trials across 433 conditions. There are 18 research doctors associated with this hospital, such as Jeffrey Taub, MD, Roland L. Chu, Alissa M. Martin, and Meret Henry, MD.Area of expertise
1Human Immunodeficiency Virus Infection
Global Leader2Leukemia
Global LeaderBCR-ABL1 fusion positive
ABL-class fusion positive
FLT3 negative
Top PIs
Jeffrey Taub, MDWayne State University/Karmanos Cancer Institute7 years of reported clinical research
Studies Lymphoma
Studies Brain Tumor
13 reported clinical trials
55 drugs studied
Roland L. ChuChildren's Hospital of Michigan7 years of reported clinical research
Studies Neuroblastoma
Studies Ganglioneuroblastoma
8 reported clinical trials
24 drugs studied
Alissa M. MartinChildren's Hospital of Michigan4 years of reported clinical research
Studies Tumors
Studies Cancer
8 reported clinical trials
34 drugs studied
Meret Henry, MDChildren's Hospital of Michigan7 years of reported clinical research
Studies Leukemia
Studies Lymphoma
7 reported clinical trials
36 drugs studied
Clinical Trials running at Children's Hospital of Michigan
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Brain Tumor
Acute Leukemia
Germ Cell Tumors
Osteosarcoma
Leukemia
Tumors
Rhabdomyosarcoma
Lymphoblastic Leukemia-Lymphoma
Stem Cell Transplantation
for Leukemia
This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical \[haplo\]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). HCT is considered standard of care treatment for patients with high-risk acute leukemia and MDS. In HCT, patients are given very high doses of chemotherapy and/or radiation therapy, which is intended to kill cancer cells that may be resistant to more standard doses of chemotherapy; unfortunately, this also destroys the normal cells in the bone marrow, including stem cells. After the treatment, patients must have a healthy supply of stem cells reintroduced or transplanted. The transplanted cells then reestablish the blood cell production process in the bone marrow. The healthy stem cells may come from the blood or bone marrow of a related or unrelated donor. If patients do not have a matched related donor, doctors do not know what the next best donor choice is. This trial may help researchers understand whether a haplo related donor or a MUD HCT for children with acute leukemia or MDS is better or if there is no difference at all.
Recruiting2 awards Phase 3
Venetoclax + Chemotherapy
for Acute Myeloid Leukemia
This trial is testing whether adding venetoclax to standard chemotherapy can help young patients with relapsed AML. Venetoclax works by blocking a protein that helps cancer cells survive, making it easier for the chemotherapy to kill them. The study aims to find better treatment options for these patients who have limited choices. Venetoclax has been shown to improve overall survival in older and unfit patients with newly diagnosed acute myeloid leukemia when combined with lower intensity therapies.
Recruiting2 awards Phase 34 criteria
Revumenib + Chemotherapy
for Relapsed/Refractory Leukemia
This phase II trial tests the safety and best dose of revumenib in combination with chemotherapy, and evaluates whether this treatment improves the outcome in infants and young children who have leukemia that has come back (relapsed) or does not respond to treatment (refractory) and is associated with a KMT2A (MLL) gene rearrangement (KMT2A-R). Leukemia is a cancer of the white blood cells, where too many underdeveloped (abnormal) white blood cells, called "blasts", are found in the bone marrow, which is the soft, spongy center of the bones that produces the three major blood cells: white blood cells to fight infection; red blood cells that carry oxygen; and platelets that help blood clot and stop bleeding. The blasts crowd out the normal blood cells in the bone marrow and spread to the blood. They can also spread to the brain, spinal cord, and/or other organs of the body. The leukemia cells of some children have a genetic change in which a gene (KMT2A) is broken and combined with other genes that typically do not interact with one another; this is called "rearranged". This genetic rearrangement alters how other genes are turned on or off in the cell, turning on genes that drive the development of leukemia. Patients with KMT2A rearrangement have higher risk for cancer coming back after treatment. Revumenib is an oral medicine that directly targets the changes that occur in a cell with a KMT2A rearrangement and has been shown to specifically kill these leukemia cells in preclinical laboratory settings and in animals. Drugs used in chemotherapy, such as vincristine, prednisone, asparaginase, fludarabine and cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to find out if the combination of revumenib and chemotherapy would be safe and/or effective in treating infants and young children with relapsed or refractory KMT2A-R leukemia.
Recruiting1 award Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Children's Hospital of Michigan?
Children's Hospital of Michigan is a medical facility located in Detroit, Michigan. This center is recognized for care of Human Immunodeficiency Virus Infection, Leukemia, Brain Tumor, Sickle Cell Anemia, Tumors and other specialties. Children's Hospital of Michigan is involved with conducting 309 clinical trials across 433 conditions. There are 18 research doctors associated with this hospital, such as Jeffrey Taub, MD, Roland L. Chu, Alissa M. Martin, and Meret Henry, MD.